[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369057-105":59,"doc-detail-369057-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-pan-cancer-characterization-of-irak2-as-a-potential-prognostic-biomarker-and-therapeutic-target-with-validation-in-hepatocellular-carcinoma","Comprehensive pan-cancer characterization of IRAK2 as a potential prognostic biomarker and therapeutic target with validation in hepatocellular carcinoma","","Inflammation-driven signaling shapes tumor microenvironments and immune responses, yet the cancer-wide relevance of interleukin-1 receptor–associated kinase 2 (IRAK2) remains insufficiently defined. This study evaluates IRAK2 expression across cancer types, transcript and single-cell patterns, prognostic value, and mechanistic links. It also tests associations with immune infiltration, immune checkpoints, mutational burden, microsatellite instability, RNA modifications, DNA methylation, and drug sensitivity. In hepatocellular carcinoma, IRAK2 knockdown reduces tumor cell proliferation in vitro and in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-pan-cancer-characterization-of-irak2-as-a-potential-prognostic-biomarker-and-therapeutic-target-with-validation-in-hepatocellular-carcinoma/369057/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-pan-cancer-characterization-of-irak2-as-a-potential-prognostic-biomarker-and-therapeutic-target-with-validation-in-hepatocellular-carcinoma/369057.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological role of IRAK2 motivates this study?","Question",{"text":112,"@type":113},"IRAK2 is described as a mediator of Toll-like receptor and interleukin-1 receptor signaling, which influences inflammation-related regulation of the tumor microenvironment and immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was IRAK2 analyzed across cancers?",{"text":117,"@type":113},"The study evaluated IRAK2 expression patterns across multiple cancer types using multiple databases and multi-dimensional datasets, including transcript variants and single-cell distribution, and assessed prognostic significance and biological functions.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports IRAK2’s relevance in hepatocellular carcinoma?",{"text":121,"@type":113},"Both in vitro and in vivo experiments showed that IRAK2 knockdown markedly reduced the proliferative capacity of hepatocellular carcinoma cells, supporting IRAK2 as a potential therapeutic target and biomarker.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369057,1790214723,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Dong et al. BMC Cancer (2026) 26:157 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15474-1](https://doi.org/10.1186/s12885-025-15474-1)  \nRESEARCH Open Access  \nComprehensive pan-cancer characterization of IRAK2 as a potential prognostic biomarker and therapeutic target with validation in hepatocellular carcinoma  \nHaiJian Dong 1,2†, Yuanqian Yao 1,2†, Qun Niu 1,2†, Xueqing Gong 1,2, Yu Mou 1,2, Zijian Zeng 1,2 and Hui Li 1,2*  \nAbstract  \nBackground Inflammation plays a critical role in cancer initiation and progression by modulating the tumor microenvironment and immune responses. Interleukin-1 receptor–associated kinase 2 (IRAK2) is a key mediator of the Toll-like receptor and interleukin-1 receptor signaling pathways, its pan-cancer expression patterns, genomic and epigenetic features, immune-related roles, and clinical relevance remain unclear.  \nMethods The expression patterns of IRAK2 across multiple cancer types, transcript variants, single-cell distribution, prognostic significance, and biological functions were comprehensively evaluated through analyses of multiple databases and multi-dimensional datasets. Furthermore, the correlations of IRAK2 with the immune microenvironment, epigenetic modifications, and drug sensitivity were investigated. The potential role of IRAK2 in hepatocellular carcinoma was further explored through both in vitro and in vivo experiments.  \nResults Aberrant expression of IRAK2 was observed in the majority of cancer types, with a relatively high proportion of expression detected in macrophages, and was found to be associated with the prognosis of certain cancers. In most cancer types, IRAK2 expression showed significant correlations with immune cell infiltration, the cancerimmunity cycle, major histocompatibility complex molecules, immune checkpoints, tumor mutational burden, microsatellite instability, RNA modifications (including m1A, m5C, and m6A), and DNA methylation sites. Both in vitro and in vivo experiments demonstrated that knockdown of IRAK2 markedly reduced the proliferative capacity of hepatocellular carcinoma cells.  \nConclusion The present study highlights the potential of IRAK2 expression as a novel biomarker for predicting the prognosis and immunotherapeutic response across various human cancers.  \nKeywords Interleukin-1 receptor–associated kinase 2 (IRAK2), Pan-cancer analysis, Cancer microenvironment, Computational biology and bioinformatics  \n†HaiJian Dong, Yuanqian Yao and Qun Niu contributed equally and are Co-first authors.  \n*Correspondence: Hui Li[lihui@cdutcm.edu.cn](lihui@cdutcm.edu.cn)  \n1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China  \n2Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nDong et al. BMC Cancer (2026) 26:157  \nIntroduction  \nMalignant tumors are among the leading contributors to the global disease burden, representing an u","cbCaiqtzOf50XEkR","https://ap.wps.com/l/cbCaiqtzOf50XEkR","pdf",7883500,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Cancer burden and therapeutic limitations\n## Inflammation and tumor microenvironment\n## IRAK2 and immune signaling context","[{\"question\":\"What biological role of IRAK2 motivates this study?\",\"answer\":\"IRAK2 is described as a mediator of Toll-like receptor and interleukin-1 receptor signaling, which influences inflammation-related regulation of the tumor microenvironment and immune responses.\"},{\"question\":\"How was IRAK2 analyzed across cancers?\",\"answer\":\"The study evaluated IRAK2 expression patterns across multiple cancer types using multiple databases and multi-dimensional datasets, including transcript variants and single-cell distribution, and assessed prognostic significance and biological functions.\"},{\"question\":\"What evidence supports IRAK2’s relevance in hepatocellular carcinoma?\",\"answer\":\"Both in vitro and in vivo experiments showed that IRAK2 knockdown markedly reduced the proliferative capacity of hepatocellular carcinoma cells, supporting IRAK2 as a potential therapeutic target and biomarker.\"}]","Comprehensive pan-cancer characterization of IRAK2 as a potential prognostic biomarker and therapeutic target with validation in hepatocellular carcinoma | PDF",1790180425,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc0e7a89719886ed6cad38d9b5ade14a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4867538155c3d1d9a89d9fa7d572597.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d84735c3f7dd4d486dfe6e5492124542.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e76ba26a88e6cc735cab47f5d7349b6.webp",980,1306]